Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Neurocrine Biosciences, Inc shares valued at $4,830,458 were sold by Gano Kyle on Jan 16 ’26. At $132.70 per share, Gano Kyle sold 36,400 shares. The insider’s holdings dropped to 140,407 shares worth approximately $19.01 million following the completion of this transaction.
Also, KYLE GANO purchased 36,400 shares, netting a total of over 4,853,940 in proceeds.
Before that, Norwalk Leslie V had sold 5,000 shares from its account. In a trade valued at $761,144, the Director traded Neurocrine Biosciences, Inc shares for $152.23 each. Upon closing the transaction, the insider’s holdings decreased to 5,000 shares, worth approximately $1.01 million.
As published in a research note from Morgan Stanley on January 08, 2026, Neurocrine Biosciences, Inc [NBIX] has been rated down from an Overweight to an Equal-weight and the price target has been revised to $175. Analysts at Citigroup started covering the stock with ‘”a Buy”‘ outlook in a report released in late October. As of July 21, 2025, Truist has initiated its “Buy” rating for NBIX. Earlier on July 10, 2025, Goldman initiated its rating. Their recommendation was “a Buy” for NBIX stock.
Analyzing NBIX Stock Performance
On last trading session, Neurocrine Biosciences, Inc [NASDAQ: NBIX] rose 0.65% to $135.41. The stock’s lowest price that day was $133.72, but it reached a high of $136.19 in the same session. During the last five days, there has been a surge of approximately 2.38%. Over the course of the year, Neurocrine Biosciences, Inc shares have dropped approximately -5.48%.
Is Neurocrine Biosciences, Inc subject to short interest?
Stocks of Neurocrine Biosciences, Inc saw a sharp rise in short interest on 2025-12-31 jumping by 79314.0 shares to 4.07 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 3.99 million shares. A jump of 1.95% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 4.27 of the overall float, the days-to-cover ratio (short ratio) jumped to 4.27.
Which companies own the most shares of Neurocrine Biosciences, Inc (NBIX)?
In terms of Neurocrine Biosciences, Inc share price expectations, FactSet research, analysts set an average price target of 177 in the next 12 months, up nearly 31.56% from the previous closing price of $134.54. Analysts anticipate Neurocrine Biosciences, Inc stock to reach 198 by 2026, with the lowest price target being 146. In spite of this, 14 analysts ranked Neurocrine Biosciences, Inc stock as Buy at the end of 2026. On April 15, 2025, Needham assigned a price target of “a Buy” to the stock and upgraded coverage with a $138.
